Syndax Announces Pricing of Public Offering of Common Stock
Syndax Pharmaceuticals, Inc. (SNDX)
Last syndax pharmaceuticals, inc. earnings: 3/3 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.syndax.com
Company Research
Source: PR Newswire
WALTHAM, Mass., April 30, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today the pricing of an underwritten public offering of 5,555,556 shares of its common stock at a price to the public of $18.00 per share. The gross proceeds to Syndax from this offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $100 million. The offering is expected to close on May 4, 2020, subject to customary closing conditions. Additionally, Syndax granted the underwriters a 30-day option to purchase up to 833,333 additional shares of common stock at the public offering price, less underwriting discounts and commissions. All of the shares of common stock in the offering will be sold by Syndax.Citigroup and Cowen are acting as joint book-running managers for the offeri
Show less
Read more
Impact Snapshot
Event Time:
SNDX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SNDX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SNDX alerts
High impacting Syndax Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
SNDX
News
- Syndax Reports Preliminary 2025 Financial Highlights and Provides Business Updates at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- Syndax Reports Preliminary 2025 Financial Highlights and Provides Business Updates at the 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswire
- Syndax Pharmaceuticals (NASDAQ:SNDX) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=SNDX&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall MarketBeat
- Syndax and World Orphan Drug Alliance to Launch a Multi-Regional Managed Access Program, Expanding Access to Revuforj® (revumenib) Outside the U.S.GlobeNewswire
- Syndax Announces Presentation at the 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswire
SNDX
Earnings
- 11/3/25 - Beat
SNDX
Sec Filings
- 1/12/26 - Form 8-K
- 12/19/25 - Form 8-K
- 12/1/25 - Form 4
- SNDX's page on the SEC website